Upload Avatar (500 x 500)
Youqian Wu
Medical School
Zhejiang University
Zhejiang
Language: Chinese, English
Tumor
Immunotherapy
New Target Drug
Asthma
Airway Inflammation
Pd-L1
Egfr
Gsk3Α
Arih1
Lung Cancer
Areas of Focus
- Tumor Immunotherapy and New Target Drug Development
- Asthma and Airway Inflammation Immunotherapy
Work Experience
- 2013-2016 - Zhejiang University, College of Life Sciences - Master's Student
- 2016-2019 - Zhejiang University, School of Medicine - Doctoral Student
- 2019-2021 - Zhejiang University, School of Medicine - Postdoctoral Researcher in Tumor Immunotherapy
- 2021.07-present - Zhejiang University, Fourth Affiliated Hospital - Associate Researcher
Academic Background & Achievements
- 2013-2016 Master of Science: Zhejiang University, College of Life Sciences
- 2016-2019 Doctor of Science: Zhejiang University, School of Medicine
- Research on PD-L1 protein degradation pathways
- Established high-throughput drug screening model based on PD-L1 membrane protein
- Identified new E3 ubiquitin ligase ARIH1 for PD-L1 protein
- Discovered new mechanism of EGFR-GSK3α-ARIH1 pathway in tumor immunity
- Received Chinese invention patent for combination drug targeting EGFR resistance mutation C797S in lung cancer
